GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jun 9, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jun 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-repurchase, stock-buyback
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on June 9, 2025, that it has purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for many public companies.
Key Players & Entities
- GSK plc (company) — The company making the share repurchase.
- Merrill Lynch International (company) — The corporate stockbroker acting on behalf of GSK.
- June 2025 (date) — The reporting period for the transaction.
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on GSK plc's transactions in its own shares during the month of June 2025.
Who is acting as GSK's stockbroker for these transactions?
Merrill Lynch International is acting as GSK's corporate stockbroker for these share purchases.
What type of shares did GSK purchase?
GSK purchased its own ordinary shares of 31 1/4 pence each.
Does the filing specify the number of shares repurchased?
No, the filing states that GSK has purchased 'the following number of the Company's ordinary shares' but does not list the specific quantity in the provided text.
What is GSK's principal executive office address?
GSK's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 9, 2025 regarding GSK plc (GLAXF).